Healthcare's Valuation Disconnect Signals Opportunity for Asia's Wealth Allocators
The healthcare sector is currently trading at a significant discount to the broader market, presenting a compelling opportunity for wealth allocators in Asia. This disconnect between healthcare equities and the overall market has been a persistent theme for the past two years, driven by political uncertainty in the United States, rising interest rates, and the surge in capital flowing into AI and technology stocks. However, beneath the headline weakness, the healthcare sector's fundamentals remain robust across multiple sub-sectors.
One key factor driving this opportunity is the sector's undervaluation. Healthcare equities are trading at approximately 17 times forward earnings, compared to 21 times for the S&P 500, a discount well below the long-term average. This undervaluation is particularly pronounced in the medtech sub-sector, which has compressed to around 18 times earnings, despite delivering strong organic revenue growth and earnings-per-share growth. The current dislocation in valuations presents a strategic entry point for investors seeking to build healthcare exposure at attractive levels.
Innovation is a key driver of long-term growth in the healthcare sector. New products and treatment modalities are creating entirely new revenue pools, such as the untapped opportunity in cardiovascular medicine represented by lipoprotein(a) (Lp(a)). Several companies, including Novartis and Amgen, are in late-stage trials for Lp(a) therapies, which could become a multi-billion-dollar market. In medtech, robotic surgery continues to advance with the introduction of AI-driven features, and the continuous glucose monitoring market is projected to grow significantly.
Artificial intelligence (AI) is emerging as a cost and efficiency lever across the healthcare sector, rather than a disruptive threat. In pharma and biotech, AI is being used to accelerate drug development, improve patient selection for clinical trials, and predict toxicity profiles, potentially saving billions in drug development costs. For health insurance companies, AI enables automation of invoice processing and contract management. In medtech, heavy regulatory requirements create natural barriers that protect hardware-based businesses from software disruption.
Mergers and acquisitions (M&A) activity is accelerating in the healthcare sector, particularly in biopharma. The 20 largest biopharma companies hold over $1 trillion in combined financial firepower, and major transactions in 2025 and early 2026 underscore the ongoing cycle. M&A is seen as an imperative rather than an option, as patent expirations loom large over big pharma, threatening hundreds of billions in revenue. The current dislocation in valuations and the sector's defensive qualities make healthcare an increasingly logical complement to concentrated technology positions in portfolios.
In conclusion, the healthcare sector's undervaluation, robust fundamentals, and innovation-driven growth present a compelling opportunity for wealth allocators in Asia. While valuations provide the entry point, innovation and AI are key drivers of long-term growth. M&A activity is accelerating, and the sector's defensive qualities make it a strategic investment for portfolios. As the tide turns and investors seek more defensive places to invest, healthcare is poised to offer significant returns for those who recognize its potential.
